Drug Trial Radar · NCT05116891
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jul 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Sep 22, 2021
Primary completion
Jun 23, 2023
Study completion Jun 23, 2023
Sponsor
- Lead sponsor
- Cantargia ABIndustry
- Sponsor type
- Industry
- First posted
- Nov 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).
Conditions
- Advanced Solid Tumors
- Colorectal Cancer
- Non Small Cell Lung Cancer
- Biliary Tract Cancer
Interventions
CAN04 (nadunolimab)Drug
FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP
mFOLFOXDrug
mFOLFOX/CAN04
DTXDrug
DTX/CAN04
G/CDrug
G/C/CAN04
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of CAN04 in combination with selected standard hemotherapy regimens and to establish MTD and/or RP2D.Time frame: Until 30 days after the last dose of study treatment (EOT visit) in Phase 1
- To assess the preliminary efficacy of CAN04 in combination with chemotherapy regimens measured as tumour response.Time frame: Until approximately 3 years after last treatment in Phase 2.
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Institut Bergonie
Bordeaux, France
Centre Eugene Marquis
Rennes, France
EDOG Institut de Cancerologie de l'Ouest - PPDS
Saint-Herblain, Boulevard Jacques Monod, France
Centre Georges François Leclerc
Dijon, Côte-d'Or, France
Hospital Universitari Vall D'Hebron
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.